Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – SEPT 9, 2019  – Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a

Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA

Zurich-Schlieren, Switzerland, August 8, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced the appointment of Nicolas Leupin, M.D., MBA, to the role of Chief Medical Officer and Member of

Zurich-Schlieren, Switzerland, August 6, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application

Pamela A. Trail, Ph.D., to transition from Chief Scientific Officer to strategic consultant; Daniel Steiner, Ph.D., to assume leadership of research organization Zurich-Schlieren, Switzerland, June 11, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a

Research & Development: MP0250 (VEGF x HGF) in MM: Additional patient data from ongoing Phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment MP0250 in combination with osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Zurich-Schlieren, April 16, 2019.  At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy to maintain initial vision gains in all patients on a true fixed 12-week

Zurich-Schlieren, March 29, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin®

Zurich-Schlieren, March 19, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today published the invitation to the Annual General Meeting 2019. The Annual General Meeting will be held on Tuesday,